BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/340/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 01:54:43 2024-07-17 pm EDT | ||
| 0.158 EUR | +28.46% |
|
| Current month | -24.76% | ||
| 1 month | -24.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.158 | +28.46% |
| 24-07-16 | 0.123 | -17.45% |
| 24-07-15 | 0.149 | +15.50% |
| 24-07-12 | 0.129 | -28.73% |
| 24-07-11 | 0.181 | +47.15% |
Real-time Boerse Frankfurt Warrants
Last update July 17, 2024 at 01:54 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VD3YF0 |
| ISIN | DE000VD3YF07 |
| Date issued | 2024-04-11 |
| Strike | 340 $ |
| Maturity | 2024-12-20 (156 Days) |
| Parity | 10 : 1 |
| Emission price | 1.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.55 € |
|---|---|
| Lowest since issue | 0.095 € |
| Spread | 0.034 € |
| Spread % | 17.71% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Warrants
- Warrant
